Lupin has announced a new partnership with Honeywell and said that it will use Honeywell’s Solstice Air HFO-1234ze, a low global warming potential (LGWP) propellant, in Lupin metered dose inhalers. The announcement did not specify whether Lupin intends to transition existing MDIs to HFO-1234ze or whether it plans to develop new MDIs with the new propellant; however, in a workshop at RDD Europe 2025 that was co-presented by the two companies, Lupin said that it was focused on reformulation.
Honeywell Sustainability and Decarbonization President Jeff Dormo commented, “Solstice Air can play a critical role in ensuring that Lupin life-saving devices provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions. By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements.”
Lupin CEO Vinita Gupta said, “Lupin’s partnership with Honeywell underscores our commitment to delivering high-quality medicines while working towards a healthier, more sustainable future for our patients and communities worldwide. By integrating Solstice Air in our products, we are not only enhancing patient care, but we are also significantly reducing environmental impact.”
Read the Lupin press release.
